Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for aneurysmal subarachnoid hemorrhage
NL-OMON48636Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of eculizumab in subarachnoid hemorrhage (SAH) and brain hemorrhage (ICH) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Concentration of C5a in cerebrospinal fluid. Started Oct 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
subarachnoid hemorrhage (SAH)brain hemorrhage (ICH)
Beyond the preview
Go deeper on NL-OMON48636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48636.